Grunnleggende statistikk
| CIK | 820608 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to QuantRx Biomedical Corporation
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 22, 2022 Commission File Number 000-17119 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter. |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPORATIO |
|
| August 16, 2022 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPORATI |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| March 31, 2022 |
NT 10-K 1 form12b25-03312022110356.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ x ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N- |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| November 15, 2021 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPORATIO |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTR |
|
| April 15, 2021 |
10-K 1 qtxb10kdec312020.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| April 1, 2021 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| November 17, 2020 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| November 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| August 14, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| May 20, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| May 15, 2020 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| April 14, 2020 |
QTXB / QuantRX Biomedical Corp. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| March 30, 2020 |
QTXB / QuantRX Biomedical Corp. NT 10-K - - OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| November 19, 2019 |
QTXB / QuantRX Biomedical Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| November 14, 2019 |
QTXB / QuantRX Biomedical Corp. NT 10-Q - - NT 10-Q 1 form12b25-11142019011105.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N- |
|
| August 15, 2019 |
QTXB / QuantRX Biomedical Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 14, 2019 |
QTXB / QuantRX Biomedical Corp. NT 10-Q - - OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| May 20, 2019 |
QTXB / QuantRX Biomedical Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| May 15, 2019 |
QTXB / QuantRX Biomedical Corp. NT 10-Q NT 10-Q 1 form12b25-05152019080512.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N- |
|
| April 16, 2019 |
QTXB / QuantRX Biomedical Corp. ANNUAL REPORT (Annual Report) 10-K 1 qtxb10kdec312018.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| April 1, 2019 |
QTXB / QuantRX Biomedical Corp. OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| November 19, 2018 |
EXHIBIT 10.1 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated October 8, 2018, is made by and between QuantRx Biomedical Corporation, a Nevada corporation (“Seller”), and Preprogen LLC, a Delaware limited liability company (“Buyer”). Buyer and Seller are collectively referred to herein as the “Parties” and each individually as a |
|
| November 19, 2018 |
QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| November 14, 2018 |
QTXB / QuantRX Biomedical Corp. NT 10-Q NT 10-Q 1 form12b25-11142018101150.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N- |
|
| August 20, 2018 |
QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 14, 2018 |
QTXB / QuantRX Biomedical Corp. NT 10-Q NT 10-Q 1 form12b25-08142018120821.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N- |
|
| May 21, 2018 |
QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| May 15, 2018 |
QTXB / QuantRX Biomedical Corp. NT 10-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| April 17, 2018 |
QTXB / QuantRX Biomedical Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| March 30, 2018 |
QTXB / QuantRX Biomedical Corp. NT 10-K OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| December 21, 2017 |
EX-10.6 7 ex10-6.htm WARRANT, DATED DECEMBER 14, 2017 Exhibit 10.6 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STAT |
|
| December 21, 2017 |
Exhibit 10.4 Exhibit 10.4 INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (?Agreement?) is entered into as of December 14, 2017 (the ?Effective Date?), by and between QuantRX Biomedical Corporation, a Nevada Corporation (?Licensee?), and Preprogen LLC, a Delaware corporation (?Licensor?). RECITALS: WHEREAS, Licensor and Licensee are parties to that certain Asse |
|
| December 21, 2017 |
Exhibit 10.1 Exhibit 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this ?Agreement?), dated December 14, 2017, is made by and between QuantRx Biomedical Corporation, a Nevada corporation (?Seller?), and Preprogen LLC, a Delaware limited liability company (?Buyer?). Buyer and Seller are collectively referred to herein as the ?Parties? and each individually as a ?Party?. WHEREAS, the |
|
| December 21, 2017 |
Exhibit 10.5 Exhibit 10.5 ESCROW AGREEMENT (Basic Three Party Escrow) THIS ESCROW AGREEMENT is entered into as of December 14, 2017, by and among Preprogen LLC, a Delaware limited liability company (?Party A?), QuantRx Biomedical Corporation, a Nevada corporation (?Party B?, and together with Party A, sometimes referred to individually as ?Party? and collectively as the ?Parties?), and JPMorgan Ch |
|
| December 21, 2017 |
EX-10.3 4 ex10-3.htm TRADEMARK ASSIGNMENT, DATED DECEMBER 14, 2017 Exhibit 10.3 TRADEMARK ASSIGNMENT AGREEMENT This TRADEMARK ASSIGNMENT AGREEMENT (this “Trademark Assignment Agreement”) is made as of December 14, 2017 by and between QuantRx Biomedical Corporation, a Nevada corporation (“Assignor”), and Preprogen LLC, a Delaware limited liability company (“Assignee”). WHEREAS, Assignor and Assigne |
|
| December 21, 2017 |
8-K 1 qtxb8kdec152017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2017 QUANTRX BIOMEDICAL CORPORATION (Exact name of Registrant as specified in its Charter) Nevada 000-17119 33-0202574 (State or ot |
|
| December 21, 2017 |
Exhibit 10.2 Exhibit 10.2 PATENT ASSIGNMENT AGREEMENT This PATENT ASSIGNMENT AGREEMENT (?Agreement?) is made as of December 14, 2017, by and between QuantRx Biomedical Corporation, a Nevada corporation (?Assignor?), and Preprogen LLC, a Delaware limited liability company (?Assignee?). WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of December 14, 2017 |
|
| November 20, 2017 |
QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| November 20, 2017 |
EX-10.1 2 ex10-1.htm FORM OF CONVERTIBLE PROMISSORY DEMAND NOTE. Exhibit 10.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is made as of July 1, 2017 and between QuantRx Biomedical Corp. (the “Company”), a Nevada corporation, with offices at 10190 SW 90th Avenue, Tualatin, OR 97123 and the purchaser identified on the signature page hereto (the “Purchaser”). WHEREAS, the |
|
| November 14, 2017 |
QTXB / QuantRX Biomedical Corp. 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| October 5, 2017 |
QTXB / QuantRX Biomedical Corp. AMENDMENT NO. 1 TO FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 Q |
|
| October 5, 2017 |
QTXB / QuantRX Biomedical Corp. ESP QuantRx Biomedical Corporation - FORM correspondence October 5, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 21, 2017 |
Exhibit 10.1 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE |
|
| August 21, 2017 |
QTXB / QuantRX Biomedical Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 14, 2017 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| May 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| May 15, 2017 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| April 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| March 29, 2017 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| December 2, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| November 14, 2016 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| August 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 15, 2016 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| August 15, 2016 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| May 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| May 16, 2016 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| April 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| March 30, 2016 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| August 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 13, 2015 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| July 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| July 22, 2015 |
Convertible Promissory Demand Note Exhibit 10.1 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE |
|
| May 15, 2015 |
QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| April 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| March 31, 2015 |
QuantRX Biomedical THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| March 26, 2015 |
QuantRx Biomedical Corporation - FORM 8-k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2015 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| March 4, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2015 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| March 4, 2015 |
Exhibit 99.1 For Immediate Release QuantRx® Biomedical Provides Update on Technological Progress of its Genomic Diagnostics Platforms Well Positioned in the Emerging Field of Fetal Genomics TUALATIN, OR – March 3, 2015 – QuantRx® Biomedical Corporation (“QuantRx” or the “Company”) (OTCBB:QTXB), an emerging provider of innovative healthcare solutions for feminine care, laboratory based point-of-car |
|
| February 25, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2015 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| February 25, 2015 |
QuantRx® Biomedical Provides Update on Corporate Developments Exhibit 99.1 QuantRx® Biomedical Provides Update on Corporate Developments TUALATIN, OR-(Marketwired - Feb 25, 2015) - QuantRx® Biomedical Corporation ("QuantRx" or the "Company") (OTCQB: QTXB), an emerging provider of innovative healthcare solutions for feminine care, point-of-care diagnostics, laboratory diagnostics and genomic testing, all of which leverage its robust portfolio of patented inte |
|
| November 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C |
|
| November 14, 2014 |
QTXB / QuantRX Biomedical Corp. NT 10-Q - - THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| August 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 14, 2014 |
QTXB / QuantRX Biomedical Corp. NT 10-Q - - THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| May 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUA |
|
| May 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO |
|
| May 15, 2014 |
- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| May 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 Q |
|
| April 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL |
|
| April 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| April 14, 2014 |
Exhibit 3.6 |
|
| April 14, 2014 |
Exhibit 3.5 |
|
| March 31, 2014 |
- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| November 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORP |
|
| November 14, 2013 |
- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATI |
|
| May 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORAT |
|
| May 14, 2013 |
- THIS IS A NT 10-Q/A ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| May 14, 2013 |
- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| April 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO |
|
| April 1, 2013 |
- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . |
|
| November 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANT |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORP |
|
| October 26, 2012 |
QuantRx Biomedical Corporation 10190 SW90th Avenue, No. 4690, Tualatin, Oregon 97123 October 26, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Kevin L. Vaughn, Accounting Branch Chief RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2011 Filed Ap |
|
| October 2, 2012 |
QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 October 2, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Kevin L. Vaughn, Accounting Branch Chief RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2011 Filed April 17, 2012 File |
|
| August 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPOR |
|
| August 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORAT |
|
| August 14, 2012 |
- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: July 31, 2012 Estimated average burden hours per response . |
|
| May 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| May 15, 2012 |
- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . |
|
| April 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| March 27, 2012 |
- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . |
|
| March 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2012 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| February 17, 2012 |
QTXB / QuantRX Biomedical Corp. / BALK MATTHEW Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74765N109 (CUSIP Number) December 31 , 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 15, 2012 |
QTXB / QuantRX Biomedical Corp. / ADELMAN JASON T Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74765N109 (CUSIP Number) December 31 , 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 2) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUAN |
|
| January 9, 2012 |
QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 January 9, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Martin James, Senior Assistant Chief Accountant RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2010 Filed April 14, 20 |
|
| December 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUAN |
|
| December 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BI |
|
| November 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA |
|
| November 14, 2011 |
OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . |
|
| November 7, 2011 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2011 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| October 28, 2011 |
QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 October 28, 2011 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Martin James, Senior Assistant Chief Accountant RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2010 Filed April 14, 2 |
|
| October 7, 2011 |
QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 October 7, 2011 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Martin James, Senior Assistant Chief Accountant RE: Quantrx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2010 Filed April 14, 20 |
|
| August 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| August 15, 2011 |
OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . |
|
| July 14, 2011 |
QuantRx Biomedical Corporation Provides Corporate Update Exhibit 99.1 QuantRx Biomedical Corporation Provides Corporate Update PORTLAND, Ore., July 14, 2011 /PRNewswire/ - QuantRx® Biomedical Corporation (OTCQB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms, is pleased to announce that following the successful resolution and full settlement of all matters re |
|
| July 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14 , 2011 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| July 8, 2011 |
SETTLEMENT AGREEMENT AND RELEASE SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release ("Agreement") is entered into by and between NuRx Pharmaceuticals, Inc. |
|
| July 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7 , 2011 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| May 20, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| May 13, 2011 |
OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . |
|
| April 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| April 14, 2011 |
Exhibit 3.6 CERTIFICATE OF DESIGNATION OF THE RELATIVE RIGHTS AND PREFERENCES OF THE SERIES B CONVERTIBLE PREFERRED STOCK OF QUANTRX BIOMEDICAL CORPORATION The undersigned, the Chief Executive Officer of QuantRx Biomedical Corporation, a Nevada corporation (the “Company”), in accordance with the provisions of Section 78.195 of the Nevada Revised Statutes, does hereby certify that, pursuant to the |
|
| March 30, 2011 |
OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . |
|
| January 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31 , 2010 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No. |
|
| November 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-17119 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2009 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report |
|
| September 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commi |
|
| September 1, 2010 |
QuantRx Biomedical Consolidates Operations to Oregon For Immediate Release QuantRx Biomedical Consolidates Operations to Oregon DOYLESTOWN, PA – September 1, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced that it will be consolidating its operations in order to better serve its growing market demands. |
|
| August 9, 2010 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 21 Prospectus Supplement No. 21 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| August 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| July 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commissio |
|
| July 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commissio |
|
| June 9, 2010 |
For Immediate Release QuantRx Biomedical Submitted a 510(k) Application to FDA for Thyroid Point-of-Care Testing System Following Successful Completion of Studies Showing Quantitative Results DOYLESTOWN, PA – June 9, 2010 – QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has completed clinical testing of the Q-Reader™ thyroid testing system. |
|
| June 9, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commission |
|
| May 17, 2010 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 20 Prospectus Supplement No. 20 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| May 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commissi |
|
| May 6, 2010 |
For Immediate Release QuantRx Biomedical Announces Board of Directors Updates Company Mourns Passing of Board Member Arthur Hull Hays, Jr; Appoints Two New Independent Directors DOYLESTOWN, PA – May 6, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced the appointment of two new independent directors to its Board of Directors; one of the appointments is a replacement for the seat vacated by Arthur Hull Hayes, Jr. |
|
| April 7, 2010 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 19 Prospectus Supplement No. 19 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| March 31, 2010 |
QN DIAGNOSTICS, LLC FINANCIAL STATEMENTS Table of Contents QN DIAGNOSTICS, LLC FINANCIAL STATEMENTS Table of Contents Report of Independent Registered Public Accounting Firm 2 Balance Sheet as of December 31, 2009 3 Statement of Operations for the Period from July 30, 2009 (inception) to December 31, 2009 4 Statement of Cash Flows for the Period from July 30, 2009 (inception) to December 31, 2009 5 Statement of Members’ Equity for the Period from July 30, |
|
| March 31, 2010 |
FLUOROPHARMA, INC. (a development stage company) FINANCIAL STATEMENTS Table of Contents FLUOROPHARMA, INC. (a development stage company) FINANCIAL STATEMENTS Table of Contents Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations 4 Statements of Cash Flows 5 Statements of Stockholders’ Equity 6 Notes to Financial Statements 7 1 To the Board of Directors and Shareholders FluoroPharma, Inc. REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING |
|
| March 23, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) (Amendment No. 1)* QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74765N109 (CUSIP Number) Sherbrooke Partners, |
|
| February 9, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 74765N109 (CUSIP Number) December 31, 2009 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 4, 2010 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 18 Prospectus Supplement No. 18 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| January 29, 2010 |
QuantRx Biomedical to Acquire NuRx Pharmaceuticals Combination Strengthens Financial and Competitive Position DOYLESTOWN, PA ? January 29, 2010 ? QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. |
|
| January 29, 2010 |
VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of January , 2010, by and among QuantRx Biomedical Corp. |
|
| January 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commis |
|
| January 29, 2010 |
EXECUTION COPY AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 29, 2010 BY AND AMONG QUANTRX BIOMEDICAL CORPORATION, NP ACQUISITION CORPORATION AND NURX PHARMACEUTICALS, INC. |
|
| January 29, 2010 |
VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of January , 2010, by and among QuantRx Biomedical Corp. |
|
| January 29, 2010 |
QuantRx Biomedical to Acquire NuRx Pharmaceuticals Combination Strengthens Financial and Competitive Position DOYLESTOWN, PA – January 29, 2010 — QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. |
|
| January 29, 2010 |
EXECUTION COPY AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 29, 2010 BY AND AMONG QUANTRX BIOMEDICAL CORPORATION, NP ACQUISITION CORPORATION AND NURX PHARMACEUTICALS, INC. |
|
| January 29, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commis |
|
| November 20, 2009 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 17 Prospectus Supplement No. 17 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA |
|
| November 5, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary proxy statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive proxy state |
|
| October 26, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary proxy statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive proxy state |
|
| August 17, 2009 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 16 Prospectus Supplement No. 16 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| August 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| August 14, 2009 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2009 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 5, 2009 | ||
| August 5, 2009 | ||
| August 5, 2009 | ||
| August 5, 2009 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of , 2009, by and between QuantRx Biomedical Corporation, a Nevada corporation (the “Company”), and Sasha Afanassiev (the “Executive”). |
|
| August 5, 2009 | ||
| August 5, 2009 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of , 2009, by and between QuantRx Biomedical Corporation, a Nevada corporation (the “Company”), and William Fleming (the “Executive”). |
|
| August 5, 2009 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of , 2009, by and between QuantRx Biomedical Corporation, a Nevada corporation (the ?Company?), and Walter Witoshkin (the ?Executive?). |
|
| August 5, 2009 | ||
| August 5, 2009 | ||
| August 5, 2009 | ||
| August 5, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2009 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 21, 2009 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 15 Prospectus Supplement No. 15 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| May 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| May 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2009 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| April 16, 2009 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 14 Prospectus Supplement No. 14 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| April 15, 2009 |
EX-21.1 LIST OF SUBSIDIARIES Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2008 Organized Under Laws of: Percentage of Voting Power FluoroPharma, Inc. Delaware 57.78 % |
|
| April 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR |
|
| February 13, 2009 |
Filed by Bowne Pure Compliance OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| December 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| December 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17 |
|
| December 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A Amendment No. 1 to Form 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-17119 |
|
| December 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 |
|
| December 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 24, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| December 18, 2008 |
QuantRx Biomedical Corporation 267-880-1595 267-880-1596 [email protected] December 18, 2008 VIA EDGAR TRANSMISSION AND OVERNIGHT DELIVERY Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Lynn Dicker Re: QuantRx Biomedical Corporation Form 10-KSB for year ended December 31, 2007 Filed March 31, 2008 Form 10-Q for the |
|
| December 9, 2008 |
Michael D. Helsel 212-801-6962 212-805-9284 [email protected] December 9, 2008 VIA EDGAR TRANSMISSION AND OVERNIGHT DELIVERY Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Lynn Dicker Re: QuantRx Biomedical Corporation Form 10-KSB for year ended December 31, 2007 Filed March 31, 2008 Form 10-Q for the period ended June 30 |
|
| November 17, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 13 Prospectus Supplement No. 13 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| November 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA |
|
| August 29, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 12 Prospectus Supplement No. 12 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| August 27, 2008 |
QuantRx Biomedical Corporation Promissory Bridge Note THIS BRIDGE NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| August 27, 2008 |
August , 2008 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Bridge Loan Letter Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this ?Agreement?) between (the ?Lender?) and QuantRx Biomedical Corporation, a Nevada corporation (the ?Borrower?), pursuant to which the Lender, on the terms and conditions |
|
| August 27, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 27, 2008 |
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| August 22, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 11 Prospectus Supplement No. 11 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| August 20, 2008 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 15, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 10 Prospectus Supplement No. 10 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl |
|
| August 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| August 8, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 9 Prospectus Supplement No. 9 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem |
|
| July 28, 2008 |
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| July 28, 2008 |
QuantRx Biomedical Corporation Senior Secured Promissory Bridge Note THIS BRIDGE NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| July 28, 2008 |
Very truly yours, By: Name: Walter W. Witoshkin Title: Chairman & CEO QuantRx Biomedical Corporation June , 2008 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Bridge Loan Letter Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this “Agreement”) between (the “Lender”) and QuantRx Biomedical Corporation, a Nevada corporation (the “Borrower”), pursuant to which the Lender, on the terms and conditions pr |
|
| July 28, 2008 |
STOCK PLEDGE AGREEMENT Stock Pledge Agreement (this “Agreement”), dated as of June , 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation, with its principal place of business at 100 South Main Street, Suite 300, Doylestown, Pennsylvania 18901 (the “Pledgor”) and (the “Secured Party”). |
|
| July 28, 2008 |
PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT THIS PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT (this “Agreement”) is entered into as of this th day of June, 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation (the “Pledgor”), with its principal address at 100 S. |
|
| July 28, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 21, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 8 Prospectus Supplement No. 8 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem |
|
| May 15, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| April 4, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 7 Prospectus Supplement No. 7 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem |
|
| March 31, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-17119 QUANTRX BIOMEDICAL CORPORATION ( |
|
| March 31, 2008 |
Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2007 EX-21.1 LIST OF SUBSIDIARIES Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2007 Organized Under Laws of: Percentage of Voting Power FluoroPharma, Inc. Delaware 57.78 % |
|
| March 5, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 6 Prospectus Supplement No. 6 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem |
|
| February 29, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| January 30, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 5 Prospectus Supplement No. 5 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 QUANTRX BIOMEDICAL COR |
|
| January 29, 2008 |
January 23, 2008 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Letter Loan Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this “Agreement”) between Platinum Long Term Growth VII LLC (the “Lender”) and QuantRx Biomedical Corporation, a Nevada corporation (the “Borrower”), pursuant to which the Lender |
|
| January 29, 2008 |
QUANTRX BIOMEDICAL CORPORATION Senior Secured Convertible Promissory Note THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| January 29, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| January 29, 2008 |
STOCK PLEDGE AGREEMENT Stock Pledge Agreement (this “Agreement”), dated as of January 23, 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation, with its principal place of business at 100 South Main Street, Suite 300, Doylestown, Pennsylvania 18901 (the “Pledgor”) and PLATINUM LONG TERM GROWTH VII LLC, with a business address of 152 West 57th Street, 54th Floor, New York, New York 10019 (the “Secured Party”). |
|
| January 29, 2008 |
PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT THIS PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT (this “Agreement”) is entered into as of this 23rd day of January, 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation (the “Pledgor”), with its principal address at 100 S. |
|
| January 29, 2008 |
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| December 31, 2007 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2007 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| November 29, 2007 |
sc13gza Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. |
|
| November 19, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 4 Prospectus Supplement No. 4 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 QUANTRX BIOMEDICAL CORPORATION This Prospectus Supplement No. 4 supplements ou |
|
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORAT |
|
| October 25, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 3 Prospectus Supplement No. 3 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 QUANTRX BIOMEDICAL CORPORATION This Prospectus Supplement No. 3 supplements our prospectus dated June 22, 2007, as supplemented by Pr |
|
| October 24, 2007 |
QUANTRX BIOMEDICAL CORPORATION Senior Secured Convertible Promissory Note THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| October 24, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 16, 2007 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 0-17119 (Commission File Number) 33-0202574 (IRS Employer Identification No. |
|
| October 24, 2007 |
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. |
|
| October 24, 2007 |
October , 2007 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Letter Loan Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this “Agreement”) between (the “Lender”) and QuantRx Biomedical Corporation, a Nevada corporation (the “Borrower”), pursuant to which the Lender, on the terms and conditions provid |
|
| August 20, 2007 |
Table of Contents Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. |
|
| August 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL |
|
| July 13, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 1 Prospectus Supplement No. 1 to Prospectus dated June 22, 2007 QUANTRX BIOMEDICAL CORPORATION This Prospectus Supplement No. 1 supplements our prospectus dated June 22, 2007. The shares of our common stock that are the subject of the prospectus have been registered to permit their resale to the public by the selling |
|
| July 6, 2007 |
FLUOROPHARMA, INC. (a development stage company) AUDITED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2006 AND 2005 AND FOR THE YEARS THEN ENDED AND FOR THE PERIOD JUNE 13, 2003 (INCEPTION) THROUGH DECEMBER 31, 2006 (UNAUDITED) TABLE OF CONTENTS PAGE - INDEPENDENT AUDITOR'S REPORT ............................................ 2 FINANCIAL STATEMENTS Balance Sheets ........................................ |
|
| July 6, 2007 |
QUANTRX BIOMEDICAL CORPORATION Pro Forma Condensed Combined Financial Statements March 31, 2007 (unaudited) QuantRx Biomedical Corporation Pro Forma Condensed Combined Financial Statements Index to Pro Forma Condensed Combined Financial Statements Introduction to Unaudited Pro Forma Condensed Combined Financial Statements 1 Unaudited Pro Forma Condensed Combined Balance Sheet 2 Unaudited Pro Forma |
|
| July 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 19, 2007 QuantRx Biomedical Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 0-17119 (Commission File Numbe |
|
| July 6, 2007 |
FLUOROPHARMA, INC. (a development stage company) REVIEWED FINANCIAL STATEMENTS AS OF MARCH 31, 2007 AND FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006 AND FOR THE PERIOD JUNE 13, 2003 (INCEPTION) THROUGH MARCH 31, 2007 (UNAUDITED) TABLE OF CONTENTS PAGE - ACCOUNTANTS' REVIEW REPORT .............................................. 2 FINANCIAL STATEMENTS Balance Sheets ............................ |
|
| June 25, 2007 |
As filed with the U.S. Securities and Exchange Commission on June 22, 2007 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 22, 2007 Registration No. 333-142130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 to FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QuantRx Biomedical Corporation (Name of small business issuer in its charter) Nevada 3841 330202574 (State o |
|
| May 15, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION |
|
| April 16, 2007 |
As filed with the U.S. Securities and Exchange Commission on April 13, 2007 Table of Contents As filed with the U.S. Securities and Exchange Commission on April 13, 2007 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QuantRx Biomedical Corporation (Name of small business issuer in its charter) Nevada 3841 330202574 (State or jurisdiction of incorporation or org |
|
| March 29, 2007 |
exv7w19 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made this 6th day of February, 2007, between Robert & Lisa Allegra (“Buyer”), and Mark Capital, LLC (“Seller”). |
|
| March 29, 2007 |
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is made this 6th day of February, 2007, between Sydney F. |
|
| March 29, 2007 |
exv7w20 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made this 6th day of February, 2007, between Rick van den Toorn (“Buyer”), and Mark Capital, LLC (“Seller”). |
|
| March 29, 2007 |
Quantrx BioMedical Corporation Table of Contents OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
